Form 4: Olema Pharmaceuticals Director Andrew Rappaport Acquires 23,000 Stock Options

Director Andrew Rappaport acquired 23,000 stock options in Olema Pharmaceuticals, Inc. on June 14, 2024.

Summary

• Andrew Rappaport, a director of Olema Pharmaceuticals, Inc., acquired 23,000 stock options on June 14, 2024.
• The exercise price of these options is $12.36.
• The options vest in 12 equal monthly installments starting from June 14, 2024, contingent upon continuous service.
• Full vesting will occur at the next annual meeting if not fully vested by then, also subject to continuous service.
• The options expire on June 14, 2034.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative news about the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company directors. It's common for directors to receive stock options as part of their compensation.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates